BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rojas-Chavarro LF, de Mora F. Extrapolation: Experience gained from original biologics. Drug Discov Today 2021;26:2003-13. [PMID: 34022458 DOI: 10.1016/j.drudis.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 de Mora F, Howles CM. Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get? Drug Discov Today 2022:S1359-6446(22)00171-4. [PMID: 35490965 DOI: 10.1016/j.drudis.2022.04.022] [Reference Citation Analysis]
2 Alsamil AM, Giezen TJ, Egberts TC, Doevendans E, Leufkens HG, Gardarsdottir H. Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: a 20-year follow-up study of originators and biosimilars. European Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ejps.2022.106227] [Reference Citation Analysis]
3 Ribaldone DG, Tribocco E, Rosso C, Armandi A, Vernero M, Bugianesi E, Astegiano M, Saracco GM, Caviglia GP. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. J Clin Med 2021;10:3387. [PMID: 34362184 DOI: 10.3390/jcm10153387] [Reference Citation Analysis]